| Serial Number | 87174403 |
| Word Mark | DAFIDA |
| Filing Date | Friday, September 16, 2016 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Tuesday, March 31, 2020 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, January 31, 2017 |
| Goods and Services | Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; Pharmaceuticals, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations for skin care used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma eye drops and decongestant formulations; sterile ointments for medical use; ocular wetting solutions, artificial tears and formulations pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, skin rejuvenators, rehydrating creams, and lotions for the face and body |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, September 21, 2016 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | ACTAVIS HOLDCO US, INC. |
| Party Type | 21 - New Owner After Publication |
| Legal Entity Type | 03 - Corporation |
| Address | PARSIPPANY, NJ 07054 |
| Party Name | Allergan Sales, LLC |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Parsippany, NJ 07054 |
| Party Name | Allergan Sales, LLC |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Parsippany, NJ 07054 |
| Event Date | Event Description |
| Wednesday, June 3, 2020 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Tuesday, June 2, 2020 | ABANDONMENT - NO USE STATEMENT FILED |
| Wednesday, July 17, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, July 16, 2019 | EXTENSION 5 GRANTED |
| Thursday, July 11, 2019 | EXTENSION 5 FILED |
| Thursday, July 11, 2019 | TEAS EXTENSION RECEIVED |
| Thursday, March 28, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, March 26, 2019 | EXTENSION 4 GRANTED |
| Tuesday, March 26, 2019 | EXTENSION 4 FILED |
| Tuesday, March 26, 2019 | TEAS EXTENSION RECEIVED |
| Wednesday, September 19, 2018 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, September 17, 2018 | EXTENSION 3 GRANTED |
| Monday, September 17, 2018 | EXTENSION 3 FILED |
| Monday, September 17, 2018 | TEAS EXTENSION RECEIVED |
| Tuesday, February 20, 2018 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, February 16, 2018 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Friday, February 16, 2018 | EXTENSION 2 GRANTED |
| Friday, February 16, 2018 | EXTENSION 2 FILED |
| Friday, February 16, 2018 | TEAS EXTENSION RECEIVED |
| Wednesday, September 13, 2017 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, September 11, 2017 | EXTENSION 1 GRANTED |
| Monday, September 11, 2017 | EXTENSION 1 FILED |
| Monday, September 11, 2017 | TEAS EXTENSION RECEIVED |
| Tuesday, September 12, 2017 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Friday, August 18, 2017 | FAX RECEIVED |
| Wednesday, August 16, 2017 | TEAS EXTENSION RECEIVED |
| Wednesday, July 5, 2017 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Tuesday, March 28, 2017 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, January 31, 2017 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, January 31, 2017 | PUBLISHED FOR OPPOSITION |
| Wednesday, January 11, 2017 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, December 22, 2016 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, December 21, 2016 | ASSIGNED TO EXAMINER |
| Wednesday, September 21, 2016 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Tuesday, September 20, 2016 | NEW APPLICATION ENTERED IN TRAM |